Compare · NVO vs PTCT
NVO vs PTCT
Side-by-side comparison of Novo Nordisk A/S (NVO) and PTC Therapeutics Inc. (PTCT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PTCT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 35.1x PTCT ($6.13B).
- Over the past year, NVO is down 12.1% and PTCT is up 48.3% - PTCT leads by 60.3 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 6 for PTCT).
- Both have 25 recent analyst ratings on file.
- Company
- Novo Nordisk A/S
- PTC Therapeutics Inc.
- Price
- $48.65+3.65%
- $73.42+3.42%
- Market cap
- $215.46B
- $6.13B
- 1M return
- -2.08%
- -3.13%
- 1Y return
- -12.07%
- +48.28%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- News (4w)
- 9
- 6
- Recent ratings
- 25
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
PTC Therapeutics Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest PTCT
- PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile
- Director Schmertzler Michael sold $1,805,411 worth of shares (25,000 units at $72.22) as part of a pre-agreed trading plan (SEC Form 4)
- EXEC. VP AND CLO Boulding Mark Elliott exercised 2,813 shares at a strike of $25.69 and sold $204,127 worth of shares (2,813 units at $72.57) as part of a pre-agreed trading plan (SEC Form 4)
- PTC Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
- CHIEF EXECUTIVE OFFICER Klein Matthew B. sold $705,722 worth of shares (10,292 units at $68.57), decreasing direct ownership by 3% to 383,868 units (SEC Form 4) to cover taxes
- Director Sollie-Zetlmayer Hege Elisabeth was granted 6,000 shares, increasing direct ownership by 13% to 52,526 units (SEC Form 4)
- New insider Sollie-Zetlmayer Hege Elisabeth claimed ownership of 46,526 shares (SEC Form 3)
- SEC Form 10-Q filed by PTC Therapeutics Inc.
- PTC Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits